Skip to main content
Equibles
LGND logo

LGND · Ligand Pharmaceuticals Inc · Analyst Estimates

Track LGND — free

Use LGND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LGND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$322.75 +5.42 (+1.71%) At close · Oct 30 Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$6.43B
Shares
20.00M
Volume · Oct 30 344.37K Avg daily vol (3M) 241.18K

Analyst Estimates

Compare analyst forecasts for Ligand Pharmaceuticals Inc across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-31 23:54 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
9.23
9.49
9.74
10
9.35
9.31
9.32
9.24
1
1
1
1
Revenue
USD
Publication date not stated
283.30M
291.35M
299.19M
11
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
10.51
12.19
13.46
10
11.96
11.95
11.93
11.83
0
0
2
2
Revenue
USD
Publication date not stated
351.38M
381.00M
403.13M
10
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
2.59
2.92
3.13
9
3.01
2.99
3.01
3.19
1
1
1
1
Revenue
USD
Publication date not stated
88.75M
96.72M
102.60M
11
 — — — — — — — —

Q ending 2027-03-31

Analyst estimates for Q ending 2027-03-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
2.30
2.30
2.30
2
2.30
2.30
2.37
2.30
1
0
0
0
Revenue
USD
Publication date not stated
76.14M
76.14M
76.14M
1
 — — — — — — — —
Key facts CIK 886163 CUSIP 53220K504 13F (30d) 134 filings 125 filers Visit website Investor relations